PharmaCyte Biotech, Inc.
PMCB
$0.9411
$0.00730.78%
NASDAQ
| 04/30/2025 | 01/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 8.67% | -16.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 8.50% | -13.24% | |||
| Operating Income | -8.50% | 13.24% | |||
| Income Before Tax | 485.83% | -107.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 485.83% | -107.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 485.83% | -107.22% | |||
| EBIT | -8.50% | 13.24% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 461.67% | -106.66% | |||
| Normalized Basic EPS | -134.48% | 21.94% | |||
| EPS Diluted | 461.67% | -106.66% | |||
| Normalized Diluted EPS | -134.48% | 21.94% | |||
| Average Basic Shares Outstanding | -1.51% | -8.86% | |||
| Average Diluted Shares Outstanding | -1.51% | -8.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||